HC Wainwright Forecasts BiomX’s Q1 Earnings (NYSEMKT:PHGE)

BiomX Inc. (NYSEMKT:PHGE) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for BiomX in a report issued on Tuesday, April 1st. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.42) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. The consensus estimate for BiomX’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for BiomX’s Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.08) EPS and FY2028 earnings at ($1.84) EPS.

BiomX Stock Performance

BiomX has a 1 year low of $0.48 and a 1 year high of $4.99. The firm has a market cap of $13.89 million, a PE ratio of -0.76 and a beta of 1.38. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.51. The company has a fifty day moving average of $0.71 and a 200-day moving average of $0.75.

Hedge Funds Weigh In On BiomX

Several hedge funds have recently added to or reduced their stakes in PHGE. JPMorgan Chase & Co. bought a new stake in BiomX in the fourth quarter valued at about $314,000. Allostery Investments LP bought a new stake in shares of BiomX in the 4th quarter valued at about $470,000. Finally, Alyeska Investment Group L.P. bought a new position in BiomX during the 4th quarter worth approximately $632,000. Institutional investors own 40.57% of the company’s stock.

About BiomX

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.